4 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Dementia by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 618 ongoing clinical trials involving Dementia
Of the 618 trials,250 trials are in Phase III
Furthermore, 189 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Dementia by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Dementia, a Central Nervous System Indication. North America boasts of the highest number of ongoing clinical trials involving Dementia. Asia-Pacific and Europe are among some of the other prominent regions involved in Dementia-related drug trials.

Eisai Co Ltd: The leading ongoing Dementia-related clinical trials sponsor

Eisai Co Ltd, a Japan-based pharmaceutical company, is the top sponsor for Dementia-related ongoing clinical trials.

Eli Lilly and Co, Otsuka Holdings Co Ltd, Alector Inc, Avanir Pharmaceuticals Inc, and Georgetown University are a few other notable sponsors involving Dementia.

A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Dementia

Olanzapine (Zyprexa), Donepezil hydrochloride (Aricept, Donepezil, E2020), and Memantine Hydrochloride (Namenda/ Ebixa/ Axura/ Memary/ Ebix/ Memantine Akatinol/Abixa) are among the key marketed drugs involving Dementia.

Olanzapine (Zyprexa), a 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) Antagonist; D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Antagonist, is indicated to treat both negative and positive symptoms of schizophrenia, acute mania with bipolar disorder, agitation, and psychotic symptoms in dementia, and it is one of the few drugs that can be used effectively in the management of the symptoms of psychotic disorders in adults. The drug is marketed globally including in the United States of America, Australia, France, Germany, and Japan by Eli Lilly and Co. Olanzapine was first approved in 1992 and formulated as an injectable solution for intramuscular or intravenous route of administration.

Donepezil hydrochloride (Aricept, Donepezil, E2020), an Acetylcholinesterase Inhibitor, is indicated for the treatment of dementia of the Alzheimer’s type and Lewy body dementia. The drug is marketed globally including in the United States of America, Australia, France, Germany, and Japan by Eisai Co Ltd. Donepezil hydrochloride was first approved in 1996 and formulated as film-coated tablets and tablets for oral route of administration.